Dataset from PONENTE: A Multicenter, Open-label, Phase 3b Efficacy and Safety Study of Benralizumab 30 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use in Adult Patients With Severe Eosinophilic Asthma on High Dose Inhaled Corticosteroid Plus Long-acting β2 Agonist and Chronic Oral Corticosteroid Therapy
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009937
下载链接
链接失效反馈官方服务：
资源简介：
This is a study designed to evaluate efficacy and safety of Benralizumab in reducing the Oral
Corticosteroid (OCS) use in adult patients with severe asthma who are receiving OCS with or
without additional asthma controller medications.
创建时间：
2025-02-10
